Browse current and previous editions of Switzer Report
Plenty of small, unprofitable ASX companies are barely covered by brokers, yet are doing genuinely interesting work. I’ve found two that are having a real crack at big global problems, one in energy-efficient AI chips and the other in hospital data.
Let’s run through the week’s ratings changes from the seven brokers monitored daily by FNArena, including a takeover-driven upgrade for Global Lithium Resources, a Buy call on Evolution Mining, and a downgrade to Sell for New Hope Corporation after its share price run.
An economist and two market veterans on this week's Switzer Show, recorded the night before the RBA decision: how many more rate rises are coming, how far house prices fall, and which shorted names the analysts still back.
Friday Close Change Change % Change Week % Dow Jones 51,828.62 478.64 0.93% -0.20% S&P 500 7,743.41 39.28 0.51% 0.63% NASDAQ 27,068.72 129.34 0.48% 1.21% […]
Here are two fixed-interest exchange-traded funds to consider.
Michael Gable, Managing Director of Fairmont Equities, says Perseus Mining (PRU) is set to extend its rally, with the gold price poised to break out of a six-month consolidation.
WAM Capital has had a horrid year, losing almost a third in value over the last 12 months. Is it time to get out? Commonwealth Bank (CBA) has fallen back to around $150.00. Do the major brokers still have ‘sell’ recommendations? If I am 75, can I still contribute to super? I put a limit order on the ASX and it got purged before the expiry date. How could this happen?
Three interest rate rises are now on the table according to some economists, and I think that call is wrong, and dangerous for the economy. Here's why I'm sitting on cash until the picture clears.
A 25-year record of rising dividends and market-beating returns makes Washington H. Soul Pattinson a company worth considering – but after a strong rally since March, I explain why it isn't cheap on current numbers.
This week's Hot Stock is James Hardie Industries, with Morgans' Raymond Chan explaining why his research team has upgraded JHX to Accumulate following the company's Investor Day, while trimming the target price to A$43.
Getting drugs past the brain's own security system is one of biotech's toughest problems. I've found four ASX-listed companies – Telix, Noxopharm, Neurizon and Ceretas – each at a different stage of proving they can cross the blood-brain barrier.
Let's run through the week's ratings changes from the seven brokers monitored daily by FNArena, including a swathe of upgrades led by Lovisa Holdings, a steep price-target cut for Telix Pharmaceuticals, and a dividend-driven downgrade for New Hope Corporation.
Two market analysts, a dozen companies, and two opposing views on Commonwealth Bank. Every stock named on this week's Switzer Show, with the call and who made it.
Two analysts and an airline executive on this week's Switzer Show: which sold-down tech names have the foundations to turn, where China's AI spending lands in the Australian market, and what the brokers now want to pay for CBA.
It's fair to say that this week's interest rate rise by the Fed in the US has shown that the collective consensus on stock prices that's called "the market" isn't sure what it should be doing.
You don't have credit card details available. You will be redirected to update payment method page. Click OK to continue.